DiaMedica Therapeutics (DMAC) Tax Provisions (2018 - 2026)

DiaMedica Therapeutics (DMAC) has reported Tax Provisions for 9 consecutive years, with $7000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Tax Provisions rose 16.67% year-over-year to $7000.0; the trailing twelve-month figure through Jun 2026 stood at -$4.9 million (down 33.98% YoY), and the FY2025 full-year result was -$4.9 million, down 34.11% from the prior year.
• Tax Provisions was little changed at $7000.0 in Q2 2026 per DMAC's latest filing, from $7000.0 in the prior quarter.
• Across five years, Tax Provisions topped out at $41000.0 in Q4 2022 and bottomed at -$4.9 million in Q4 2025.
• Historically, Tax Provisions has averaged -$469666.7 across 5 years, with a median of $7000.0 in 2022.
• The sharpest annual moves came in 2022 and 2024: Tax Provisions jumped 78.26% in 2022, then tumbled 16840.91% in 2024.
• Over 5 years, Tax Provisions stood at $41000.0 in 2022, then tumbled by 46.34% to $22000.0 in 2023, then sank by 16840.91% to -$3.7 million in 2024, then plunged by 33.83% to -$4.9 million in 2025, then soared by 100.14% to $7000.0 in 2026.
• According to Business Quant data, Tax Provisions over the past three periods registered $7000.0, $7000.0, and -$4.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.